All In MedTech

FDA Clearance Tracker · P040020-S014

ACRYSOF IQ RESTOR IOLS 3.0 AND 4.0 D ADD POWERS

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 20, 2009 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 20, 2009

Approved

Time to decision

164 days

Received Mar 9, 2009. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P040020-S014
Device name
ACRYSOF IQ RESTOR IOLS 3.0 AND 4.0 D ADD POWERS
Applicant location
Fort Worth, TX
Received
Mar 9, 2009
Decided
Aug 20, 2009
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P040020

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code MFK

FDA's approval statement

As written in FDA's record.

APPROVAL FOR CHANGES TO THE LABELING,REVISING THE DIRECTIONS FOR USE (DFU) AND PATIENT BROCHURE WITH UPDATED SIX-MONTHFOLLOW UP DATA FROM THE CLINICAL INVESTIGATION FOR THE LENSES. THE DEVICES, AS MODIFIEDWILL BE MARKETED UNDER THE TRADE NAME ACRYSOF IQ RESTOR INTRAOCULAR LENSES(IOLS) +3.0 D (MODELS: SN6AD1 AND MN6AD1) AND +4.0 D (MODELS: SN6AD3 ANDMN6AD3) ADD POWERS AND IS INDICATED FOR PRIMARY IMPLANTATION FOR THE VISUAL CORRECTIONOF APHAKIA SECONDARY TO REMOVAL OF A CATARACTOUS LENS IN ADULT PATIENTS WITH OR WITHOUTPRESBYOPIA, WHO DESIRE NEAR, INTERMEDIATE AND DISTANCE VISION WITH INCREASED SPECTACLEINDEPENDENCE. THE LENS IS INTENDED TO BE PLACED IN THE CAPSULAR BAG.

Source documents

Other decisions for Alcon Research, Ltd.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.